Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Minehart, H. W.
Right arrow Articles by Chalker, A. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Minehart, H. W.
Right arrow Articles by Chalker, A. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2001) 47, 360-361
© 2001 The British Society for Antimicrobial Chemotherapy

Correspondence

In vitro activity of gemifloxacin against Helicobacter pylori

Heather W. Minehart and Alison F. Chalker*,

Department of Anti-Infective Research, SmithKline Beecham Pharmaceuticals, 1250 South Collegeville Road, Collegeville, PA 19426-0989, USA

Sir,

The common gastric pathogen Helicobacter pylori is implicated in the development of chronic gastritis, duodenal and gastric ulcers, and gastric mucosa-associated lymphoid tissue (MALT) lymphoma, and there is an established link between H. pylori infection and gastric cancer. Eradication of the infection is often recommended for symptomatic . . . [Full Text of this Article]

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
J. Tankovic, C. Lascols, Q. Sculo, J.-C. Petit, and C.-J. Soussy
Single and Double Mutations in gyrA but Not in gyrB Are Associated with Low- and High-Level Fluoroquinolone Resistance in Helicobacter pylori
Antimicrob. Agents Chemother., December 1, 2003; 47(12): 3942 - 3944.
[Abstract] [Full Text] [PDF]